CSF2 and acute myeloid leukemia: Based on these findings and the fact that this patient has no known history of chronic myeloproliferative disease, a diagnosis of AML with mutated NPM1 was made and induction chemotherapy with FLAG-IDA regimen (fludarabine, cytarabine, idarubicin, and granulocyte colony stimulating factor) was started and GM-CSF was given from day 6 of the induction.